---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-023158"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2023-08-11T23:59:59+00:00"
generated_at: "2026-06-11T14:42:25.872543+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech Q2 2023 cash $32.2M; 33% CR/CRi in AML trial Phase 1B

## Summary
- R&D expense $3.9M, G&A expense $2.5M; cash runway into Q3 2024.
- Phase 1B/2 Annamycin monotherapy for soft tissue sarcoma: 73% stable disease after 2 cycles.
- Phase 1B portion of Annamycin + Cytarabine for AML completed; 33% CR/CRi rate among 6 patients.
- European Phase 1 Annamycin AML results published in British Journal of Cancer Research.
- Retained Shareholder Intelligence Services to investigate potential naked short selling.

## SEC filing metadata
- accession: 0001437749-23-023158
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2023-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774923023158/0001437749-23-023158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774923023158/mbrx20230808c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-023158
- JSON: https://secwatch.observer/filing/0001437749-23-023158.json
- Plain text: https://secwatch.observer/filing/0001437749-23-023158.txt

## Key facts
- Earnings Releases
  Moleculin Biotech, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 11, 2023, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and recent operational highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774923023158/0001437749-23-023158-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.